Discover investment opportunities in Genomics Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Genomics Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Genomics Stocks using our Smart AI Filter.
8 stocks found for "Genomics Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
1.34 Risk measure | ±55.5% Price volatility | -10.4 Valuation | 0.00% Annual yield | |||
1.92 Risk measure | ±68.6% Price volatility | -1.9 Valuation | 0.00% Annual yield | |||
1.39 Risk measure | ±92.0% Price volatility | -3.9 Valuation | 0.00% Annual yield | |||
1.82 Risk measure | ±67.7% Price volatility | -15.1 Valuation | 0.00% Annual yield | |||
1.19 Risk measure | ±53.7% Price volatility | -156.9 Valuation | 0.00% Annual yield | |||
0.89 Risk measure | ±41.9% Price volatility | 22.8 Valuation | 0.00% Annual yield | |||
0.92 Risk measure | ±45.4% Price volatility | -143.2 Valuation | 0.00% Annual yield | |||
3.05 Risk measure | ±100.0% Price volatility | -2.4 Valuation | 0.00% Annual yield |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Illumina Inc. ILMN is currently in Phase 17 of its 18-phase Adhishthana Cycle on the weekly chart. A detailed structural analysis using the Adhishthana Principles reveals deeper issues that go beyond short-term price action and offers compelling reasons why this stock should be avoided.
Read moreIn the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $52.73, denoting a -6.54% move from the preceding trading day.
Read moreThe average of price targets set by Wall Street analysts indicates a potential upside of 26.2% in Exact Sciences (EXAS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read moreNTLA stock surges 29.8% in a month, driven by gene therapy pipeline progress and growing investor attention.
Read moreLLY's move to buy Verve ignites investor interest across gene-editing stocks like CRSP, NTLA and BEAM in a booming M&A year.
Read moreTwist Bioscience (TWST) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to loss of $0.79 per share a year ago.
Read more